Targeted protein degraders continue to show differentiation from traditional small molecules in terms of both efficacy and safety. To expand the scope of targeted protein degradation (TPD), there has been significant interest throughout the industry in leveraging new E3 ligases beyond CRBN, VHL, MDM2, cIAP, and SCF.
Sep. 8, 2023
A DCAF1 Ligand Designed for Targeted Protein Degradation
compound 13
DCAF1 binder preclinical, applied to targeted protein degradation from HTS + optimization ACS Med. Chem. Lett. June 2, 2023 Novartis, Basel, CH